MG
ARQT icon

Mather Group’s Arcutis Biotherapeutics ARQT Stock Holding History

Mather Group’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-190
Closed -$3.58K – 705
2025
Q3 		$3.58K Buy
+190
New +$3K ﹤0.01% 1460
2025
Q2 		– Sell
-190
Closed -$2.97K – 676
2025
Q1 		$2.97K Buy
+190
New +$2.68K ﹤0.01% 1507
2024
Q3 		– Sell
-190
Closed -$1.88K – 1744
2024
Q2 		$1.88K Hold
190
– – ﹤0.01% 1902
2024
Q1 		$614 Buy
+190
New +$1.42K ﹤0.01% 1668

Other funds holding ARQT

SCM
Suvretta Capital Management New York $3.69B AUM 86.67% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $8.16B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $22.9B AUM 115.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return